ATE315657T1 - In hefe exprimierte heteologe g-protein- gekoppelte rezeptoren, fusionen desselben mit g- proteinen und deren verwendung im biotest - Google Patents

In hefe exprimierte heteologe g-protein- gekoppelte rezeptoren, fusionen desselben mit g- proteinen und deren verwendung im biotest

Info

Publication number
ATE315657T1
ATE315657T1 AT95910301T AT95910301T ATE315657T1 AT E315657 T1 ATE315657 T1 AT E315657T1 AT 95910301 T AT95910301 T AT 95910301T AT 95910301 T AT95910301 T AT 95910301T AT E315657 T1 ATE315657 T1 AT E315657T1
Authority
AT
Austria
Prior art keywords
protein
yeast
heterologous
expressed
nucleotide sequence
Prior art date
Application number
AT95910301T
Other languages
English (en)
Inventor
Mark Henry Pausch
Bradley Alton Ozenberger
John Richard Hadcock
Laura Alicia Price
Eileen Marie Kajkowski
Donald Richard Kirsch
Deborah Tardy Chaleff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22722547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE315657(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of ATE315657T1 publication Critical patent/ATE315657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT95910301T 1994-02-14 1995-02-14 In hefe exprimierte heteologe g-protein- gekoppelte rezeptoren, fusionen desselben mit g- proteinen und deren verwendung im biotest ATE315657T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/195,729 US5691188A (en) 1994-02-14 1994-02-14 Transformed yeast cells expressing heterologous G-protein coupled receptor

Publications (1)

Publication Number Publication Date
ATE315657T1 true ATE315657T1 (de) 2006-02-15

Family

ID=22722547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95910301T ATE315657T1 (de) 1994-02-14 1995-02-14 In hefe exprimierte heteologe g-protein- gekoppelte rezeptoren, fusionen desselben mit g- proteinen und deren verwendung im biotest

Country Status (9)

Country Link
US (6) US5691188A (de)
EP (1) EP0745130B1 (de)
JP (1) JPH09510087A (de)
AT (1) ATE315657T1 (de)
AU (1) AU1846995A (de)
CA (1) CA2183166A1 (de)
DE (1) DE69534741T2 (de)
SG (1) SG49061A1 (de)
WO (1) WO1995021925A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054402A1 (en) * 1993-03-31 2003-03-20 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US7235648B1 (en) 1993-03-31 2007-06-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US7416881B1 (en) * 1993-03-31 2008-08-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6255059B1 (en) 1993-03-31 2001-07-03 Cadus Pharmaceutical Corporation Methods for identifying G protein coupled receptor effectors
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6864060B1 (en) 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
WO1996040939A2 (en) * 1995-06-07 1996-12-19 Cadus Pharmaceutical Corporation Expression of functional vertebrate phospholipases in yeast
CA2232733A1 (en) * 1995-09-20 1997-03-27 Orikkalapat Prem Das Yeast receptor and g-protein fusion protein
AU1206397A (en) 1995-12-29 1997-07-28 Guilford Pharmaceuticals Inc. Method and kit for detection of multiple protein interactions
GB9606126D0 (en) * 1996-03-22 1996-05-22 British Biotech Pharm Biosensors
AU3055697A (en) * 1996-04-23 1997-11-12 Cadus Pharmaceutical Corporation Functional expression of heterologous adenylyl cyclase
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US5985214A (en) * 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
GB9719496D0 (en) * 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
WO1999019513A2 (en) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
US6485922B1 (en) 1997-10-10 2002-11-26 Atairgin Technologies, Inc. Methods for detecting compounds which modulate the activity of an LPA receptor
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
US6355473B1 (en) 1998-05-06 2002-03-12 Cadus Pharmaceutical Corp. Yeast cells having mutations in stp22 and uses therefor
US6733991B1 (en) * 1998-05-08 2004-05-11 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses therefor
US6280934B1 (en) 1998-05-13 2001-08-28 Millennium Pharmaceuticals, Inc. Assay for agents which alter G-protein coupled receptor activity
AU4820399A (en) * 1998-06-29 2000-01-17 Hyseq, Inc. A chemokine receptor obtained from a cdna library of fetal liver-spleen
US7081360B2 (en) 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US7273747B2 (en) * 1998-08-27 2007-09-25 Cadus Technologies, Inc. Cell having amplified signal transduction pathway responses and uses therefor
CA2343046A1 (en) * 1998-09-01 2000-03-09 Basf Aktiengesellschaft Enhanced functional expression of g protein-coupled receptors
US7094593B1 (en) 1998-09-01 2006-08-22 Basf Aktiengesellschaft Method for improving the function of heterologous G protein-coupled receptors
US6251605B1 (en) 1998-10-27 2001-06-26 Cadus Pharmaceutical Corporation Yeast cells having mutations in Cav1 and uses therefor
US6902886B1 (en) * 1998-11-06 2005-06-07 The Research Foundation Of State University Of New York Genetic assay for protein nuclear transport
US6420137B1 (en) 1998-11-25 2002-07-16 American Home Products Corporation Nucleic acid encoding human neurotensin subtype 2 receptor
US6504008B1 (en) 1999-02-01 2003-01-07 Cadus Technologies, Inc. Cell based signal generation
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US6555325B1 (en) * 1999-06-14 2003-04-29 Cadus Technologies, Inc. System for detection of a functional interaction between a compound and a cellular signal transduction component
US7223533B2 (en) 1999-09-10 2007-05-29 Cadus Technologies, Inc. Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways
CA2325169A1 (en) 1999-12-03 2001-06-03 Ndsu Research Foundation Somatostatins and method
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
IL152634A0 (en) 2000-05-04 2003-06-24 Univ Yale High density protein arrays for screening of protein activity
IL154596A0 (en) 2000-08-25 2003-09-17 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
AU2002211142A1 (en) * 2000-10-26 2002-05-06 Actar Ab Screening method using a g coupled receptor associated with a specific g protein
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7176187B2 (en) 2001-02-15 2007-02-13 Board Of Regents, The University Of Texas System Fusion proteins based upon somatostatin receptors
AU2002303277A1 (en) * 2001-04-06 2002-10-21 Vladimir Larionov Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells
WO2002083934A1 (en) * 2001-04-17 2002-10-24 Wyeth P2yac receptor involved in platelet aggregation
US20050182242A1 (en) * 2001-05-11 2005-08-18 Michael Snyder Global analysis of protein activities using proteome chips
US20030166540A1 (en) * 2001-05-30 2003-09-04 Feder John N. Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY30
MXPA03011260A (es) * 2001-06-07 2004-02-27 Wyeth Corp Receptor acoplado a proteina g y usos del mismo.
EP2327985B2 (de) 2001-06-26 2019-08-21 Senomyx, Inc. Hetero-oligomere T1R-Geschmacksrezeptoren und diese Rezeptoren exprimierende Zelllinien und deren Verwendung zur Identifizierung von Geschmacksverbindungen
DE60216115T2 (de) * 2001-08-01 2007-05-31 Merck & Co., Inc. BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
CN100488981C (zh) 2001-08-24 2009-05-20 维多利亚大学创新和发展公司 含有蛋白酶激活序列的气单胞菌溶素原及其应用
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
AU2002332027A1 (en) * 2001-10-04 2003-04-14 The Government Of The United States Of America, As Tandem repeat markers
US7445925B2 (en) * 2001-10-27 2008-11-04 Sanofi-Aventis Deutschland Gmbh Aequorin as a reporter gene in yeast
US20030232359A1 (en) * 2002-03-18 2003-12-18 Ramanathan Chandra S. Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY40_2
ATE491803T1 (de) * 2002-04-23 2011-01-15 Cargill Inc Polypeptide und biosynthetische pfade
DE10233516A1 (de) * 2002-07-23 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Identifizierung von Substanzen
US20040248323A1 (en) 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
EP3431464A3 (de) 2003-08-06 2019-07-31 Senomyx Inc. Neuartige aromastoffe, aromamodifikatoren, geschmacksstoffe, geschmacksverstärker, umami- oder süsse geschmacksstoffe und/oder -verstärker und deren verwendung
EP1786831A4 (de) 2004-07-30 2008-01-23 Cargill Inc Alanin-2,3-aminomutasen
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
CA2649215A1 (en) * 2006-04-21 2007-11-01 Novartis Ag 2,6,9-trisubstituted purine compounds as adenosine aza receptor modulators
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8148536B2 (en) 2006-04-21 2012-04-03 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
BRPI0713901A2 (pt) * 2006-06-27 2013-01-08 Biovitrum Ab compostos terapÊuticos
EP1889846A1 (de) * 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
EP2084121A1 (de) * 2006-11-10 2009-08-05 Novartis AG Cyclopentendiolmonoacetatderivate
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US7674891B2 (en) 2008-08-01 2010-03-09 International Flavors & Fragrances Inc. Nucleic acid molecules encoding GPR84
US20100209931A1 (en) * 2009-02-13 2010-08-19 Yolanda Sanchez Compositions for Identifying Novel Compositions for the Treatment of Disease and Methods of Using Same
JP2012524125A (ja) 2009-04-20 2012-10-11 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EP2621462B1 (de) 2010-10-01 2020-02-12 The Procter and Gamble Company Mundpflegezusammensetzungen mit verbessertem geschmack
CN104220875A (zh) 2010-10-19 2014-12-17 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
RS61153B1 (sr) 2011-01-07 2020-12-31 Anji Pharma Us Llc Ligand hemosenzornog receptora-osnovne terapije
WO2013113370A1 (en) * 2012-01-31 2013-08-08 Canvax Biotech S.L Gpcr with improved cell surface expression
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9809862B2 (en) * 2014-08-11 2017-11-07 Georgia Tech Research Corporation G-protein coupled receptor (GPCR)-based biosensors and uses thereof
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
JP7229223B2 (ja) * 2017-07-05 2023-02-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多重レセプター－リガンド相互作用スクリーニング
DK3710576T3 (da) 2017-11-17 2025-01-02 Iovance Biotherapeutics Inc Til-ekspansion fra finnålsaspirater og små biopsier
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
SG11202104663PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Treatment of nsclc patients refractory for anti-pd-1 antibody
MX2021004953A (es) 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Seleccion de celulas t reactivas al tumor mejoradas.
CN113272421B (zh) 2018-11-05 2025-02-18 艾欧凡斯生物治疗公司 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途
US12343380B2 (en) 2018-11-05 2025-07-01 Iovance Biotherapeutics, Inc. Expansion of TILs utilizing AKT pathways inhibitors
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20220389381A1 (en) 2019-10-25 2022-12-08 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
AU2020391231A1 (en) 2019-11-27 2022-07-14 Turnstone Biologics Corp. Method of producing tumor-reactive T cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
KR20220158727A (ko) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
EP4146794A1 (de) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Verfahren zur herstellung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (de) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4352513A2 (de) * 2021-05-18 2024-04-17 The Trustees Of Columbia University In The City Of New York Biosensoren aus lebender hefe und verfahren zur verwendung davon
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
JP2025503987A (ja) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
EP4565683A1 (de) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimäre kostimulatorische rezeptoren, chemokinrezeptoren und deren verwendung in zellulären immuntherapien
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000926A1 (en) * 1984-07-20 1986-02-13 Celltech Limited Eucaryotic expression vectors
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5284746A (en) * 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
ATE199391T1 (de) 1990-09-13 2001-03-15 Univ Duke Expression von an g-protein gekoppelten rezeptoren in hefe
US5789184A (en) * 1993-03-31 1998-08-04 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
JPH08510115A (ja) * 1993-03-31 1996-10-29 カダス ファーマシューティカルズ、インコーポレーテッド フェロモン系タンパク質代用物を産生するように操作された酵母細胞、ならびにその利用法
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor

Also Published As

Publication number Publication date
JPH09510087A (ja) 1997-10-14
DE69534741D1 (de) 2006-04-06
AU1846995A (en) 1995-08-29
US7148053B2 (en) 2006-12-12
US20090081764A1 (en) 2009-03-26
US6406871B1 (en) 2002-06-18
US5691188A (en) 1997-11-25
EP0745130B1 (de) 2006-01-11
CA2183166A1 (en) 1995-08-17
US20040023315A1 (en) 2004-02-05
DE69534741T2 (de) 2006-11-02
EP0745130A1 (de) 1996-12-04
WO1995021925A1 (en) 1995-08-17
US6607906B1 (en) 2003-08-19
SG49061A1 (en) 1998-05-18
US5846819A (en) 1998-12-08

Similar Documents

Publication Publication Date Title
ATE315657T1 (de) In hefe exprimierte heteologe g-protein- gekoppelte rezeptoren, fusionen desselben mit g- proteinen und deren verwendung im biotest
Duplay et al. Sequences of the malE gene and of its product, the maltose-binding protein of Escherichia coli K12.
NZ515913A (en) Modified chimeric polypeptides with improved pharmacokinetic properties
CA2299624A1 (en) Mammalian cytokine receptor - 11
Buggy et al. Glucagon· Glucagon-like Peptide I Receptor Chimeras Reveal Domains That Determine Specificity of Glucagon Binding (∗)
EP1369430A3 (de) Zwei menschliche G-Protein-gekoppelte Rezeptorproteine: EBV-induzierter GPCR (EBI-2) und EGD-1-ählicher GPCR
PT96714A (pt) Processo para a preparacao de receptores acoplados a proteina g hibrida
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
NZ336929A (en) Purified receptor that binds TRAIL and antibodies thereof
CA2335318A1 (en) Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction
EP1029915A3 (de) Expression von an G-Protein gekoppelten Rezeptoren in Hefe
CA2378519A1 (en) Human cytokine receptor
Svoboda et al. A cDNA construct allowing the expression of rat hepatic glucagon receptors
DK1064376T3 (da) GFR-alpha3 og dets anvendelser
Long In search of a function for the invariant chain associated with la antigens
ATE291627T1 (de) Chimäre des g-proteins
TW200510456A (en) Materials and methods relating to g-protein coupled receptor oligomers
KR950703057A (ko) 글루카곤 수용체(glucagon receptors)
AU2003293959A1 (en) Millisecond activation switch for seven-transmembrane proteins
Rached et al. Expression of the human melanocortin-2 receptor in different eukaryotic cells
Hasegawa et al. Determination of the binding site on the extracellular domain of guanylyl cyclase C to heat-stable enterotoxin
WO1999023116B1 (en) ASSAY EMPLOYING CadC FUSION PROTEINS
Molina et al. Structural domains of the insulin receptor and IGF receptor required for dimerisation and ligand binding
Wittenbrink et al. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the α2 domain
IL138585A (en) Vertebrate patched -2 protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties